TY - JOUR
T1 - Host–microbiota interactions in immune-mediated diseases
AU - Ruff, William E.
AU - Greiling, Teri M.
AU - Kriegel, Martin A.
N1 - Funding Information:
M.A.K. received salary, consulting fees, honoraria or research funds from Roche, Bristol–Meyers Squibb, AbbVie and Cell Applications, and is an employee of Roche. M.A.K. holds a patent on the use of antibiotics and commensal vaccination to treat autoimmunity and received royalties. T.M.G. received research funds from Eli Lilly and Company and Janssen Scientific Affairs. W.E.R. declares no competing interests.
Funding Information:
The M.A.K. laboratory received funding from the National Institutes of Health (NIH) (K08AI095318, R01AI118855, T32AI07019, T32DK007017-39), the O’Brien Center at Yale (NIH P30DK079310), the Yale Rheumatic Diseases Research Core (NIH P30 AR053495), the Yale Liver Center (NIH P30 DK34989), the Women’s Health Research at Yale, the Arthritis National Research Foundation, the Arthritis Foundation, and the Lupus Research Institute.
Publisher Copyright:
© 2020, Springer Nature Limited.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Host–microbiota interactions are fundamental for the development of the immune system. Drastic changes in modern environments and lifestyles have led to an imbalance of this evolutionarily ancient process, coinciding with a steep rise in immune-mediated diseases such as autoimmune, allergic and chronic inflammatory disorders. There is an urgent need to better understand these diseases in the context of mucosal and skin microbiota. This Review discusses the mechanisms of how the microbiota contributes to the predisposition, initiation and perpetuation of immune-mediated diseases in the context of a genetically prone host. It is timely owing to the wealth of new studies that recently contributed to this field, ranging from metagenomic studies in humans and mechanistic studies of host–microorganism interactions in gnotobiotic models and in vitro systems, to molecular mechanisms with broader implications across immune-mediated diseases. We focus on the general principles, such as breaches in immune tolerance and barriers, leading to the promotion of immune-mediated diseases by gut, oral and skin microbiota. Lastly, the therapeutic avenues that either target the microbiota, the barrier surfaces or the host immune system to restore tolerance and homeostasis will be explored.
AB - Host–microbiota interactions are fundamental for the development of the immune system. Drastic changes in modern environments and lifestyles have led to an imbalance of this evolutionarily ancient process, coinciding with a steep rise in immune-mediated diseases such as autoimmune, allergic and chronic inflammatory disorders. There is an urgent need to better understand these diseases in the context of mucosal and skin microbiota. This Review discusses the mechanisms of how the microbiota contributes to the predisposition, initiation and perpetuation of immune-mediated diseases in the context of a genetically prone host. It is timely owing to the wealth of new studies that recently contributed to this field, ranging from metagenomic studies in humans and mechanistic studies of host–microorganism interactions in gnotobiotic models and in vitro systems, to molecular mechanisms with broader implications across immune-mediated diseases. We focus on the general principles, such as breaches in immune tolerance and barriers, leading to the promotion of immune-mediated diseases by gut, oral and skin microbiota. Lastly, the therapeutic avenues that either target the microbiota, the barrier surfaces or the host immune system to restore tolerance and homeostasis will be explored.
UR - http://www.scopus.com/inward/record.url?scp=85086360898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086360898&partnerID=8YFLogxK
U2 - 10.1038/s41579-020-0367-2
DO - 10.1038/s41579-020-0367-2
M3 - Review article
C2 - 32457482
AN - SCOPUS:85086360898
SN - 1740-1526
VL - 18
SP - 521
EP - 538
JO - Nature Reviews Microbiology
JF - Nature Reviews Microbiology
IS - 9
ER -